Matters of legal in nature including licensing, intellectual property, and lawsuits.
RYE BROOK, N.Y.–(BUSINESS WIRE)–Oct. 21, 2019– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and Chief Executive Officer Patrick Decker and Senior Director of Investor Relations Matt Latino will present at 10:30AM Eastern Standard time / 9:30AM Central Standard... Read more
Oct 29, 2019 FRANKLIN LAKES, N.J., and WAGENINGEN, THE NETHERLANDS, October 29, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that FDA 510(k) clearance was obtained for a molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. The BD MAX™ Check-Points... Read more
Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch. Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a... Read more
Peer M. Schatz to step down as CEO to pursue new opportunities Remains as Special Advisor to facilitate a smooth transition Search started for permanent CEO to lead QIAGEN in next growth phase Thierry Bernard to act as interim CEO, working in tandem with CFO Roland Sackers Venlo, The Netherlands, October 7, 2019 – QIAGEN... Read more
FRANKLIN LAKES, N.J., Sept. 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company’s annual meeting of shareholders. Forlenza will continue on the BD board of directors, serving... Read more
Official Approval from Leading Accreditation Group Follows the Recent Addition of Listeria testing and Environmental Mapping™ capabilities to the Clear Safety™ platform MENLO PARK, CALIF. (PRWEB) SEPTEMBER 24, 2019 Clear Labs, the only automated and intelligent NGS platform purpose-built for food safety testing, today announced that its flagship product, Clear Safety, has received AOAC Performance Tested... Read more
Basel, 13 September 2019 Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment... Read more
Date: 09/11/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has filed a patent infringement suit against 10X Genomics, Inc. in the United States District Court for the District of Delaware. In the lawsuit Bio-Rad asserts that 10X Genomics infringes... Read more
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court for the Northern District of Californiaseeking to stop the infringement of its patented technology by IONpath. In... Read more
Basel, 10 September 2019 Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future... Read more